Clinical Trial Detail

NCT ID NCT03822468
Title Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Goserelin + Letrozole + Ribociclib

Anastrozole + Ribociclib

Anastrozole + Goserelin + Ribociclib

Letrozole + Ribociclib

Age Groups: adult senior

No variant requirements are available.